Advertisement

High-Throughput Screening Using Mass Spectrometry within Drug Discovery

  • Mattias RohmanEmail author
  • Jonathan Wingfield
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1439)

Abstract

In order to detect a biochemical analyte with a mass spectrometer (MS) it is necessary to ionize the analyte of interest. The analyte can be ionized by a number of different mechanisms, however, one common method is electrospray ionization (ESI). Droplets of analyte are sprayed through a highly charged field, the droplets pick up charge, and this is transferred to the analyte. High levels of salt in the assay buffer will potentially steal charge from the analyte and suppress the MS signal. In order to avoid this suppression of signal, salt is often removed from the sample prior to injection into the MS. Traditional ESI MS relies on liquid chromatography (LC) to remove the salt and reduce matrix effects, however, this is a lengthy process. Here we describe the use of RapidFire™ coupled to a triple-quadrupole MS for high-throughput screening. This system uses solid-phase extraction to de-salt samples prior to injection, reducing processing time such that a sample is injected into the MS ~every 10 s.

Key words

Mass spectrometry RapidFire™ Electrospray (ESI) High-throughput screening Triple-quadrupole mass spectrometry Mass charge (m/zIonization 

References

  1. 1.
    Awad H, Khamis MM, El-Aneed A (2015) Mass spectrometry. Review of the basics: ionization. Appl Spectrosc Rev 50(2):158–175CrossRefGoogle Scholar
  2. 2.
    Trufelli H, Palma P, Famiglini G et al (2011) An overview of matrix effects in liquid chromatography–mass spectrometry. Mass Spectrom Rev 30(3):491–509CrossRefGoogle Scholar
  3. 3.
    van Breemen RB (2010) Mass spectrometry and drug discovery. Burger’s medicinal chemistry and drug discovery. Wiley, Hoboken, NJGoogle Scholar
  4. 4.
    Zhang J, Shou WZ (2012) Mass spectrometry for quantitative in vitro ADME assays. Mass spectrometry for drug discovery and drug development. Wiley, Hoboken, NJ, pp 97–113Google Scholar
  5. 5.
    Benkestock K, Van Pelt CK, Akerud T et al (2003) Automated nano-electrospray mass spectrometry for protein-ligand screening by noncovalent interaction applied to human H-FABP and A-FABP. J Biomol Screen 8(3):247–256CrossRefGoogle Scholar
  6. 6.
    Yang M, Brazier M, Edwards R et al (2005) High‐throughput mass‐spectrometry monitoring for multisubstrate enzymes: determining the kinetic parameters and catalytic activities of glycosyltransferases. ChemBioChem 6(2):346–357CrossRefGoogle Scholar
  7. 7.
    Donegan M, Tomlinson AJ, Nair H et al (2004) Controlling matrix suppression for matrix‐assisted laser desorption/ionization analysis of small molecules. Rapid Commun Mass Spectrom 18(17):1885–1888CrossRefGoogle Scholar
  8. 8.
    Özbal CC, LaMarr WA, Linton JR et al (2004) High throughput screening via mass spectrometry: a case study using acetylcholinesterase. Assay Drug Dev Technol 2(4):373–382CrossRefGoogle Scholar
  9. 9.
    Quercia AK, LaMarr WA, Myung J et al (2007) High-throughput screening by mass spectrometry: comparison with the scintillation proximity assay with a focused-file screen of AKT1/PKB alpha. J Biomol Screen 12(4):473–480CrossRefGoogle Scholar
  10. 10.
    Forbes CD, Toth JG, Ozbal CC et al (2007) High-throughput mass spectrometry screening for inhibitors of phosphatidylserine decarboxylase. J Biomol Screen 12(5):628–634CrossRefGoogle Scholar
  11. 11.
    Leveridge M, Buxton R, Argyrou A et al (2014) Demonstrating enhanced throughput of RapidFire mass spectrometry through multiplexing using the JmjD2d demethylase as a model system. J Biomol Screen 19(2):278–286CrossRefGoogle Scholar
  12. 12.
    Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4(2):67–73CrossRefGoogle Scholar
  13. 13.
    Adam GC, Meng J, Rizzo JM et al (2015) Use of high-throughput mass spectrometry to reduce false positives in protease uHTS screens. J Biomol Screen 20(2):212–222CrossRefGoogle Scholar
  14. 14.
    Fuhrer T, Zamboni N (2015) High-throughput discovery metabolomics. Curr Opin Biotechnol 31:73–78CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Reagent and Assay DevelopmentAstraZeneca R&DMölndalSweden
  2. 2.Screening SciencesAstraZeneca R&DCambridgeUK

Personalised recommendations